AMP-activated protein kinase (AMPK) is an intracellular energy sensor that regulates metabolism in response to energy demand and supply by adjusting the ATP-generating and ATP-consuming pathways. AMPK potentially plays a critical role in diabetes and obesity as it is known to be activated by metforin and rosiglitazone, drugs used for the treatment of type II diabetes. AMPK is a heterotrimer composed of a catalytic subunit and two regulatory subunits, and . Mutations in the subunit are known to cause glycogen accumulation, leading to cardiac arrhythmias. Recently, a functional glycogen-binding domain (GBD) has been identi®ed in the subunit. Here, the crystallization of GBD in the presence of -cyclodextrin is reported together with preliminary X-ray data analysis allowing the determination of the structure by single isomorphous replacement and threefold averaging using in-house X-ray data collected from a selenomethionine-substituted protein.
Introduction
AMP-activated protein kinase (AMPK) coordinates energy metabolism in response to a variety of stimuli including exercise and adipocyte-derived hormones, resulting in tissue-speci®c changes to fatty-acid -oxidation, glycolysis, glucose transport and food intake (reviewed in Kemp et al., 1999; Hardie et al., 2003; Carling, 2004) . In this way, AMPK functions as a critical focal point for whole-body and cellular mechanisms maintaining energy homeostasis. AMPK has attracted widespread interest since the discovery that metformin, which is used to treat type II diabetes, could activate the enzyme (Fryer et al., 2002) . The importance of AMPK as a key regulator has been further highlighted by the discovery of mutations in the AMPK subunits in pigs that cause glycogen-storage disease (Milan et al., 2000) as well as in humans that affect the electrical properties of the heart (Gollob et al., 2002) .
AMPK is an heterotrimer with multiple subunit isoforms encoded by seven genes (1, 2, 1, 2, 1, 2, 3) allowing up to 12 isoenzyme combinations, each with varying tissue and subcellular expression. AMPK requires the presence of all three subunits for activity and is activated through phosphorylation on the catalytic subunit by LKB1, a serine/threonine kinase mutated in Peutz± Jeghers syndrome (Woods et al., 2003) . AMPK contains a serine/ threonine catalytic domain, an autoinhibitory domain and a subunitbinding domain. AMPK is myristoylated at the N-terminus, phosphorylated at multiple sites and contains a glycogen-binding domain (GBD) that we and others have recently identi®ed Polekhina et al., 2003) . The subunit contains two pairs of CBS domains that have been found in a number of enzymes and have been shown to bind the AMPK allosteric activator AMP (Scott et al., 2004) .
Several lines of evidence that link AMPK to glycogen exist such as glycogen synthase and glycogen phosphorylase co-localizing and coimmunoprecipitating with AMPK and mutations in the AMPK subunit leading to glycogen-storage disease in pigs, mice and humans Milan et al., 2000; Gollob et al., 2002; Hudson et al., 2003; Polekhina et al., 2003) . The identi®cation of GBD thereby provides a molecular relationship between AMPK and glycogen.
AMPK GBD is related to the N-isoamylase domain found in glycogen-branching enzyme Polekhina et al., 2003) . We have modelled GBD based on a structural alignment of several N-isoamylase domains of starch and glycogen-branching enzymes and predicted one carbohydrate-binding site on the surface of the domain (Polekhina et al., 2003) . The model is supported by mutational analysis. We now report the expression, puri®cation and crystallization of GBD and its selenomethionine-substituted L105M mutant, as well as the preliminary structure determination by single isomorphous replacement and threefold averaging using in-house X-ray data.
Experimental procedures and results

Expression and purification
The cloning, expression and puri®cation of the rat AMPK 1 subunit GBD (68±163) has been described previously (Polekhina et al., 2003) . Brie¯y, GBD was cloned into pProEX HT (Invitrogen) and expressed as a His-tag fusion protein in BL21 cells. Protein expression was induced with 1 mM IPTG for 3 h at 310 K when the cell density reached an OD 600 of 0.6. GBD was puri®ed on an Ni±agarose column and precipitated with 60% (NH) 2 SO 4 for 30 min at 277 K. The protein pellet was resuspended in 50 mM Tris±HCl pH 8.5 and desalted by gel ®ltration. The His tag was cleaved by overnight digestion at room temperature with a His-tagged TEV protease (Invitrogen). The TEV protease, the cleaved His tag and any uncleaved material were removed by a second round of puri®cation on an Ni±agarose column. GBD was further puri®ed by S100 gel®ltration chromotography (Amersham Pharmacia) in 50 mM HEPES pH 7.0.
Our attempts to determine the structure either by molecular replacement using the GBD model or by isomorphous replacement were unsuccessful. We therefore decided to introduce selenomethionine. No natural methionine residues were present in the GBD amino-acid sequence. Based on the GBD model and the structural alignment of N-isoamylase domains, Leu105 was chosen to be replaced by methionine since it was part of the hydrophobic core and two out of three N-isoamylase domains contain methionine in an equivalent position, while the third has a leucine. Site-directed mutagenesis was performed according to the manufacturer's instructions (Stratagene). The template used was pProEX HT/GBD and the oligonucleotides used were 5 H -TGGAGCAAATTGCCC ATGACTAGAAGCCAAAAC-3 H for the sense strand and 5 H -GTT-TTGGCTTCTAGTCATGGGCAATTTGCTCCA-3 H for the antisense strand. The L105M mutation was con®rmed by DNA sequencing. GBD L105M was transformed into Novagen 834 (DE3) cells. For expression, one colony was inoculated into 3 Â 100 ml minimal media (Molecular Dimensions) containing 40 mg ml À1 methionine (Sigma) and incubated overnight at 310 K with shaking. The pellet washed with water was resuspended into 3 Â 1 l minimal media (Molecular Dimensions) containing 40 mg ml À1 selenomethionine (Sigma) and incubated at 310 K with shaking until an OD 600 of 0.6 was reached, at which point protein expression was induced by the addition of 1 mM IPTG for an additional 4 h at 310 K. The puri®-cation of SeMet-GBD L105M followed the same protocol as for wildtype GBD. The incorporation of SeMet was con®rmed by MALDI mass spectrometry. The yields of wild-type and SeMet L105M GBD were 2 and 6.7 mg per litre of culture, respectively.
Crystallization
Prior to crystallization, the wild-type GBD and SeMet L105M GBD were concentrated to 14 mg ml À1 in 50 mM HEPES pH 7.0. All crystallization trials were performed at 295 K using the hanging-drop vapour-diffusion techinque. Initial screens with the wild-type GBD did not produce any crystals. Cyclodextrins have previously been used in structural studies of starch-binding and glycogen-binding proteins (Sorimachi et al., 1997; Pinotsis et al., 2003) . We have also shown that -cyclodextrin competes for binding to GBD with glycogen (Polekhina et al., 2003) . Since -cyclodextrin is only slightly soluble in water, GBD was incubated with -cyclodextrin powder on a rotating wheel at 277 K overnight. Excess -cyclodextrin was removed by centrifugation. The GBD±-cyclodextrin complex was then subjected to a variety of crystallization screens. The best crystals were grown when 2 ml GBD±-cyclodextrin was mixed with an equal volume of reservoir solution containing 100 mM MES pH 7.0, 28± 30%(w/v) PEG monomethyl ether 5000. Within a week, crystals of typical dimensions 0.1 Â 0.1 Â 0.3±0.4 mm appeared (Fig. 1a) . Crystals of selenomethionine-substituted mutant GBD L105M were obtained under the same conditions but grew to larger size (0.2 Â 0.2 Â 0.6 mm) and had a tendency to produce a larger number of single crystals (Fig. 1b) .
Preliminary X-ray analysis and structure determination
Diffraction data were collected at 100 K and recorded on a MAR 345 imaging-plate detector (MAR Research, Germany) using Cu K radiation from an in-house Rigaku RU-200 rotating-anode X-ray generator. Crystals were either¯ash-frozen from the crystallization drop or transferred into 100 mM MES pH 7.0 and 32%(w/v) PEG monomethylether 5000, with larger crystals requiring a higher PEG percentage for successful freezing. GBD crystals diffract to 2 A Ê resolution in-house ( (Matthews, 1968) . A self-rotation function did not resolve the ambiguity, as no signi®cant peak corresponding to either twofold or threefold noncrystallographic symmetry was observed.
SeMet-substituted GBD L105M crystals were prepared in anticipation of an upcoming synchrotron trip. While waiting for the synchrotron trip, the quality of the crystals was assessed using the inhouse X-ray source. We were able to easily determine the positions of three selenomethionines from the isomorphous difference Patterson maps calculated using in-house data from SeMet-substituted GBD L105M as a derivative and data from the wild-type GBD crystals as native (Fig. 3) . The phasing statistics are shown in Table 1 . The phases were improved by solvent¯attening (DM; Collaborative Computational Project, Number 4, 1994). However, the obtained electrondensity map was not unambiguously interpretable and the handedness could not be decided. As mentioned earlier, our attempts to determine the structure by molecular replacement using the GBD model were unsucessful. However, we have now established the positions of the three molecules in the unit cell as determined from the positions of the Se atoms. Using AMoRe (Navaza, 1994) and a GBD L105M model with the S atom of Met105 ®xed at the origin, we calculated the rotation function at 15±4 A Ê resolution. The top rotation peak with an R factor of 53.2% and a correlation coef®cient of 0.12 was taken as the ®rst solution. All rotation peaks were then assigned a translation vector corresponding to the second SeMet position and were considered as a possible second solution. We then X-ray diffraction pattern from a crystal of SeMet-substituted GBD L105M. ² R merge = I À hIia I, where I is the intensity measurement for a given re¯ection and hIi is the average intensity for multiple measurements of this re¯ection. ³ R iso = jF PH j À jF P j a jF P j, where F PH and F P are the derivative and native structure-factor amplitudes, respectively. § R Cullis = jF PH j AE jF P j À jF H j a jF PH j AE jF P j . } Phasing power = root-mean-square of (|F H |/E), where F H is the calculated heavy-atom structure-factor amplitude and E is the residual lack-of-closure error.
Figure 3
Six sections from the isomorphous difference Patterson map calculated at 20±4 A Ê resolution using in-house data from SeMet-substituted GBD L105M crystal as a derivative and in-house data from the wild-type GBD crystal. Contours above 3' are shown in steps of 1'. performed rigid-body re®nement using AMoRe at 15±4 A Ê resolution for each of the possible solution pairs. The best pair had an R factor of 50.7% and a correlation coef®cient of 0.27 and identi®ed the 47th rotation peak as a rotation solution corresponding to the second SeMet position. Again, all rotation solutions were assigned a translation vector according to the third SeMet position and each was considered as a possible third solution together with the best pair. After rigid-body re®nement, the best solution triple gave an R factor of 49.3%, a correlation coef®cient of 0.31 and identi®ed the 12th rotation peak as a rotation solution for the third molecule. We also performed the calculations corresponding to the alternative enantiomorph, which resulted in an R factor of 50.7% and a correlation coef®cient of 0.29 for the top solution triple. On the basis of these statistics we chose the former solution, in which two molecules are related by an approximate twofold symmetry ( = 162 ) and the third molecule is related to either of the two by an improper symmetry, thus explaining why no self-rotation peak was found. Non-crystallographic symmetry matrices were derived from the molecularreplacement solution. Threefold averaging was then incorporated into the density modi®cation in addition to solvent¯attening performed using DM (Collaborative Computational Project, Number 4, 1994) at 20±3 A Ê resolution. The resulting electron density was easily interpretable. Re®nement of the model is now in progress.
GP and DS are supported by NHMRC RD Wright Research Fellowships and MWP is a NHMRC Senior Principal Research Fellow. This work was also supported by a grant from the National Health and Medical Research Council of Australia (NHMRC) to MWP.
